Cereno Scientific’s CS585 could represent the first viable option of an IP receptor agonist for primary inhibition of thrombosis with reduced risk of bleeding as presented at the ASH Meeting
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that new preclinical data conclude that drug candidate CS585 provides a new option of activating the IP receptor to decrease platelet reactivity and could represent the first viable option for targeting the IP receptor on platelets for primary inhibition of thrombosis with a reduced risk of bleeding. The data was presented at the 65th ASH Annual Meeting & Exposition organized by the American Society of Hematology, in San Diego, US, on December
